Latest news with #Insulin
&w=3840&q=100)
Business Standard
4 days ago
- Business
- Business Standard
Biopharma stock under ₹500 plunges 4%; what should investors do?
Biocon share price today: Shares of biopharmaceutical company, Biocon, plunged over 4 per cent on Friday, August 8, 2025, logging an intraday low of ₹348.3. At 02:00 PM, Biocon shares were trading at ₹350, down by 3.87 per cent on the BSE. In comparison, BSE Sensex was trading at 80,101.63 level, down by 521 points or 0.65 per cent. So far this calendar year, the shares of the company have remained largely flat, albeit in the red territory. The total market capitalisation of the company stood at ₹47,087.86 crore. At the time of writing this report, around 4.8 million shares had changed hands on the counter, cumulatively, on the NSE and BSE. The selling at the counter came a day after the company released its earnings for the financial year 2025-2026 (Q1FY26). Biocon Q1FY26 earnings The biopharma company's revenue from operations for the quarter ended June 30, 2025, surged 15 per cent year-on-year (Y-o-Y) to ₹3,942 crore, as compared to ₹3,433 crore reported in the corresponding quarter of the last financial year. However, on a sequential basis, revenues were down by 11 per cent. Net profit for the quarter fell over 95 per cent in Q1FY26 to ₹31.4 crore as against ₹660 crore reported in the first quarter of financial year 2025-2026. Segment-wise, generics revenue advanced 6 per cent Y-o-Y to ₹697 crore in Q1FY26 as against ₹659 crore reported in the same period of the previous fiscal. Meanwhile, Biosimilars witnessed a growth of 18 per cent Y-o-Y to ₹2,458 crore during the quarter under review. Biocon's contract research, development and manufacturing (CRDMO) segment's revenue rose 11 per cent. Core earnings before interest, taxes, depreciation and amortisation (Ebitda) stood at ₹1,003 crore in Q1FY26, up from ₹903 crore reported in the year-ago period. "Key developments this quarter include the launch of Yesafili™ in Canada, our tenth biosimilar globally, and USFDA approval for Insulin Aspart, our second interchangeable biosimilar Insulin, further deepening our presence in the US insulin market," said Kiran Mazumdar-Shaw, chairperson, Biocon Group. "With execution momentum across all businesses and expanded capacity through acquisitions in the U.S. by Syngene and Biocon Generics, we are well-positioned to drive long-term value creation in FY26 and beyond,' she added. Brokerage View- Religare Broking Ravi Singh, SVP-retail research at Religare Broking, has advised investors to avoid fresh buying for now. "Biocon raised ₹4,500 crore via a qualified institutions placement (QIP) in June to consolidate its stake in Biocon Biologics and facilitate investor exits. Investors are advised to exit their long position and ignore buying fresh for now. For upside, a clear move above 370 should sustain only then we can consider buying for the upside target of ₹400, while, on downside, 345 has immediate support for now, if it fails to hold this level then further selling could be expected," he said. "On daily charts, Biocon has broken below an upward sloping trend line with a good volume spike, and a sustained move below the key support of ₹360 can trigger prices towards ₹338 and ₹330. Short-term moving average also signals pressure with prices trading below 21-day EMA," Ravi Singh added.
Business Standard
4 days ago
- Business
- Business Standard
Biocon drops after Q1 PAT tumbles 95% YoY to Rs 31 cr
Biocon fell 1.15% to Rs 360.40 after the company reported a 95.2% decline in consolidated net profit to Rs 31.40 crore despite of 15.8% jump in Net sales to Rs 3,910.10 crore in Q1 FY26 over Q1 FY25. Profit before tax (PBT) dropped 91.5% to Rs 96.90 crore in Q1 FY26 compared with Rs 1145.50 crore in Q1 FY25. The company reported a one-time gain of Rs 1,075 crore in Q1 FY25 from divestment of its branded formulations India (BFI) business. Core EBITDA stood at Rs 1,003 crore in Q1 June 2025, registering the growth of 11% compared with Rs 903 crore in Q1 FY25. Core EBITDA excludes impact of forex, R&D expense, licensing income, BFI divestment gain, and mark-to-market movement on investments. Core EBITDA margin fell to 25% in Q1 FY26 compared with Rs 26% in Q1 FY25. Revenue from generics business increased 6% YoY to Rs 697 crore during the quarter. Revenue from biosimilars business stood at Rs 2,458 crore, registering the growth of 18% YoY, driven by robust demand for the companys products across geographies. The companys contract research development & manufacturing organization (CRDMO) business reported a positive start to FY26 with revenue from operations growing 11% year-on-year to Rs 875 crore and EBITDA rising 19%. Growth was primarily driven by the continued conversion of pilot programs into long-term contracts within the Research Services business. Kiran Mazumdar-Shaw, chairperson, Biocon Group, said, Biocon opened FY26 with a strong performance, driven by continued gains in Biosimilars and CRDMO, and a steady showing in Generics. Operating Revenue rose 15% YoY to Rs 3,942 crore, with EBITDA up 19% on a like-for-like basis, demonstrating operating leverage and the robustness of our businesses. The recent QIP has strengthened our balance sheet and enables us to increase our ownership in Biocon Biologics by facilitating the exit of structured equity investors, aligning capital structure with long-term strategic priorities. Key developments this quarter include the launch of Yesafili in Canada, our tenth biosimilar globally, and USFDA approval for Insulin Aspart, our second interchangeable biosimilar Insulin, further deepening our presence in the U.S. insulin market. With execution momentum across all businesses and expanded capacity through acquisitions in the U.S. by Syngene and Biocon Generics, we are well-positioned to drive long-term value creation in FY26 and beyond. Siddharth Mittal, CEO & managing director, Biocon, said, Biocon Biologics started FY26 on a strong footing, delivering 18% year-on-year revenue growth, driven by robust demand across key markets. EBITDA rose 36% Y-o-Y on a like-to-like basis to Rs 645 crore, with a 300 bps sequential margin improvement, driven by improved operating leverage. Peter Bains, CEO & managing director, Syngene International, said, We delivered a strong first-quarter performance in line with expectations, with revenue from operations growing 11% year-on-year to Rs 875 crore and EBITDA at Rs 224 crore, reporting a growth of 19%. Growth was driven by continued momentum in research services, as pilot programs transitioned into long-term contracts. Meanwhile, the companys board approved entering into power purchase agreement and share purchase/ subscription agreement/ shareholders agreement with Pro-zeal Green Power Sixteen (PGPSPL) for purchase of solar power from captive off-site solar energy power plant. As part of this arrangement, the company will acquire a 26% stake in PGPSPL Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions like diabetes, cancer, and autoimmune diseases.
West Australian
19-07-2025
- Health
- West Australian
World Transplant Games gold medallist Colleen Ashby awarded Kellion Victory Medal
'It doesn't matter what your limitations are, let your abilities take over.' That's the mantra Kalamunda heart transplant recipient Colleen Ashby lives by 24-7, 365. A World Transplant Games gold, silver and bronze medallist, 60-year-old Ashby has made a habit of staring down challenges with a relentless work ethic, humility and boundless enthusiasm since she was diagnosed with type 1 diabetes at age nine. She had no choice but to be active, growing up with five older brothers and a Mum who told her not to let anything stand in her way. Ashby's achievements were recognised this week when she was presented with the Kellion Victory Medal at Government House. Kellion medals are presented to those who have lived with type 1 or 2 diabetes for 50 years or more. The award is named in honour of John Kellion who died at 38 because of complications caused by type 1 diabetes. Another West Australian Gordon Bunyan was announced as the new Kellion Victory Medal Ambassador. Ashby's struggle began with the crude forms of treatment for diabetes in the 1970s. 'They didn't have the plastic disposable syringes back then or the (Insulin) pens,' she said. 'It was a a big glass syringe that mum had to boil up in the morning and the gauge was like a horse needle I can tell you,' Ashby recalled. 'Lucky I had parents that never stopped me from doing anything. I did horse riding and ballroom dancing and played squash.' She graduated to aerobics instructor and a self-confessed 'gym junkie' while becoming a special needs education assistant. But then some major setbacks. Ashby broke the chromium in her shoulder, which led to surgery. Twelve months later both shoulders 'froze', a result of the type 1 diabetes. 'To regain fitness I decided to teach spin classes because I couldn't get my arms above me head but you don't need them in spin classes,' she said. 'Next thing, I had this indigestion and I was drinking Mylanta by the bottle full but my diabetic endocrinologist thought it sounded like angina so he sent me for a stress test and they said 'You'd better find a cardiologist'.' Ashby was diagnosed with ischaemic heart disease. 'From the age of 46, I had 12 stents put in over a four-year period,' she said. A heart transplant was considered but initially ruled out. 'They said it was never going to be because usually the diabetic bodies are not good (for a transplant),' she said. Six weeks after her next bout of surgery, a triple bypass, Ashby was still out of breath. More tests led to her being put on the transplant register and 12 months later, in January 2017, Ashby received a new heart. 'I was in a induced coma for four days because the new heart wouldn't start up,' she said. 'They didn't think I was going to survive because the heart wasn't working properly,' she said. 'I woke up on day five and couldn't see. The heart was working by my eyes weren't. An ophthalmologist told me the message to my brain had been damaged. It stopped getting messages of how to see. 'So I have been left legally blind with just five per cent peripheral vision in my right and nothing in my left and no central vision at all.' But it didn't stop her. Ashby has three sons, Stephen, Scott and Mark, and did not want to wallow, so she took up swimming, which would challenge her aerobically and soothe her muscles at the same time. 'I hadn't swam in five years because my shoulders had been frozen, but they had freed up after the surgery so I said to my husband 'I reckon I can still follow that black line in the bottom of the pool', so we went down to Bayswater Waves, I jumped in and took to it like a fish to water,' she said. 'Then I heard about the Transplant Games.' An international multi-sport event, the Games are held every two years and Ashby cleaned up at the 2023 version in Perth: winning a suite of medals in freestyle and backstroke. She is also into cycling and has just started a new swimming program as she is in recovery for another shoulder operation. Ashby has also authored two books, I Can See Clearly Now and Ya Gotta Laugh, about her journey. She hopes the Kellion Medal will also highlight her story and give hope to diabetics that anything is possible. 'I had three of my girlfriends all die by the time they were 30 from kidney failure who were diabetics,' she said. 'For 50 years I've been doing the exercise and the medal just proves that you can do anything in life you like provided you look after yourself and put your mind to it. 'My motto, it doesn't matter what your limitations are, let your abilities take over, really means just live the best life that you can for yourself. Don't worry about other people's expectations, just live the best life for you.' Ashby has done just that.
